The duration of neutropenia (absolute neutrophil count (ANC) p100/ll) identifies cancer patients at risk for infection. A test that precedes ANCX100/ll would be of clinical value. The immature reticulocyte fraction (IRF) reflects erythroid engraftment and hence a recovering marrow. We evaluated the IRF as predictor of marrow recovery among 90 myeloma patients undergoing their first and second (75 patients) melphalan-based autologous stem cell transplantation (Mel-ASCT). The time to IRF doubling (IRF-D) preceded ANCX100/ll in 99% of patients after the first Mel-ASCT by (mean7s.d.) 4.2371.96 days and in 97% of the patients after the second Mel-ASCT by 4.1171.95 days. We validated these findings in a group of 117 myeloma patients and 99 patients with various disorders undergoing ASCT with different conditioning regimens. We also compared the time to hypophosphatemia and to absolute monocyte countX100/ll to the time to ANCX100/ll. These markers were reached prior to this ANC end point in 55 and 25% of patients but were almost always preceded by IRF-D. We conclude that the IRF-D is a simple, inexpensive and widely available test that can predict marrow recovery several days before ANCX100/ll.
Introduction
Infection is a serious complication of antineoplastic therapy particularly in the setting of profound and prolonged myelosuppression. 1 The severity of myelosuppression has been evaluated as absolute neutrophil count (ANC)p100/ ml, absolute monocyte count (AMoC)p100/ml, 2,3 expected resolution of neutropenia in o10 days and 'early evidence of marrow recovery. 4 Unfortunately, it is difficult to predict time to resolution of neutropenia, and 'early evidence of marrow recovery' 4 is not a clearly defined end point. A test that can predict marrow recovery in an individual patient earlier than ANCX100/ml would be of clinical value.
An increase in oral mucosal neutrophils precedes neutrophil recovery by 3 days 5 but is time consuming. Other predictive tests of marrow recovery include hypophosphatemia 6 and hypouricemia, 7 both of which develop in approximately 60% of patients upon marrow recovery 6, 7 but precede ANCX500/ml by only 2-3 days and can be altered by phosphate replacement, renal failure and/or allopurinol therapy.
Increasing numbers of circulating immature reticulocytes has been proposed as a marker of marrow recovery. 8, 9 During erythropoiesis, reticulocytes are released into the circulation where they gradually lose their RNA, mature and evolve into erythrocytes. A higher proportion of circulating immature reticulocytes (high RNA content) indicates recovering marrow activity and is quantitated by automated hematology cell analyzers. 8, 9 The fluorescence intensity of the entire reticulocyte population was initially reported as the reticulocyte maturation index or the mean fluorescent index. 10, 11 Reticulocytes have now been grouped into low, middle (MFR) or high fluorescent region (HFR) corresponding to the lower, middle and higher RNA content, respectively. The immature reticulocyte fraction (IRF) measures the MFR and HFR populations and is more reproducible than the HFR. 12 We compared the time to doubling of IRF (IRF-D) to time to ANCX100/ml in 90 consecutive myeloma patients undergoing melphalan-based tandem autologous stem cell transplantation (Mel-ASCT). The IRF-D was found to be a reliable predictor of ANC recovery and preceded ANCX100/ml by several days in the overwhelming majority of patients. We also validated the predictive role of the IRF-D in two cohorts, one of 99 patients with various underlying disorders undergoing ASCT with different conditioning regimens and another of 117 myeloma patients who were treated with Mel-ASCT. In this latter group of myeloma patients, we compared the time to IRF-D with the time to AMoCX100/ml and time to a 20% drop in serum phosphate over 24 h to the time to ANCX100/ml. The effect of red blood cell transfusion and hemoglobin (Hgb) level on IRF was also analyzed for the entire study population.
Patients and methods
This study was conducted at the Myeloma Institute for Research and Therapy, the University of Arkansas for Medical Sciences, Little Rock, Arkansas. Institutional Review Board approval was obtained for this study.
Patient population
Derivation set: multiple myeloma, prospective. We conducted a prospective evaluation of 90 consecutive patients with newly diagnosed myeloma enrolled in our Total Therapy III protocol (February 2004 -April 2005 and who were undergoing Mel-ASCT. The induction phase of Total Therapy III consists of two cycles of VDT-PACE (bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide) with stem cell collection followed by tandem Mel-ASCT. All 90 patients received their first Mel-ASCT and 75 received their second Mel-ASCT at the time of this report. All patients had daily ANC and IRF values from day 0 ASCT to ANCX500/ml.
Validation set -Group 1: multiple myeloma, retrospective. We conducted a retrospective review of the medical records of 382 consecutive patients (October 1998-December 2002) with newly diagnosed myeloma enrolled in our Total Therapy II protocol 13 which relies on four cycles of induction chemotherapy followed by tandem Mel-ASCT. The 117 patients who had daily ANC, AMoC, serum phosphate and IRF values from day 0 ASCT to ANCX500/ml during their first Mel-ASCT were analyzed.
Validation set -Group 2: diseases other than myeloma, retrospective. We also reviewed the medical records of 188 patients (January 1998-July 2005) who underwent ASCT for diseases other than myeloma and received various conditioning regimens. Of these patients, 99 had daily IRF and ANC values from day 0 ASCT to ANCX500/ml.
The underlying disease for this group of 99 patients included non-Hodgkin's lymphoma (40%), Hodgkin's disease (21%), Waldenstrom's macroglobulinemia (14%), amyloidosis (10%), leukemia, solid tumor and others (15%). Conditioning regimens consisted of BEAM (BCNU, etoposide, cytarabine and melphalan) 14 (53%), melphalan (70-200 mg/m 2 ) (21%) and others (22%) ( Table 1 ). Neutrophil recovery: ANCX100/ml. Monocyte recovery: AMoCX100/ml. Hypophosphatemia: A 20% drop over 24 h in serum phosphate levels (PO4-20% drop).
Blood cell determinations

Statistical analysis
All analyses were performed with SAS 9.1 (SAS Institute Inc., Cary, NC, USA). Significant level was chosen as 0.05. We used the Student's t-test to measure the difference between time to IRF-D and time to ANCX100/ml and paired Student's t-test to compare the IRF values before and after red blood cells transfusion. We used ANOVA to test for differences in IRF-D among patients with various underlying diseases and conditioning regimens (validation set), and for differences in IRF-D according to Hgb levels divided in tertiles. 
Results
Kinetics of ANC and reticulocytes after ASCT Derivation set: 90 myeloma patients, 165 transplants, prospective ( Table 2) . The IRF-D preceded ANC4100/ml in 99% of the 90 patients undergoing their first Mel-ASCT and in 97% of these 75 patients undergoing their second Mel-ASCT. The IRF-D preceded ANCX100/ml by a mean of 4.2371.96 days and 4.1171.95 days after the first and second Mel-ASCT, respectively. IRF-N preceded ANCX100/ml in 99% of the patients after the first and second Mel-ASCT by a mean time of 2.971.4 and 2.271.1 days, respectively.
Validation set -Group 1: 117 myeloma patients, 117 transplants, retrospective. The IRF-D preceded ANCX 100/ml in 98% of patients by a mean of 5.4972.79 days while the IRF-N preceded ANCX100/ml in 93% of patients, by a mean of 4.0872.78 days ( Table 2) .
Validation set -Group 2: 99 non-myeloma patients, 99 transplants, retrospective. The kinetics of marrow recovery for the 99 patients in this group were comparable to those observed in the derivation set. The IRF-D preceded ANCX100/ml in 95% of patients by a mean of 5.4173.21 days (Table 2) . These results were observed among patients with different underlying diseases and conditioning regimens ( Table 1 ). The IRF-N preceded ANCX100/ml in 97% of patients by a mean of 3.672.6 days.
Analysis of the results obtained with the two cell analyzers (patients transplanted before and after December 2004) yielded comparable results (data not shown).
Effect of red blood cell transfusion (RBCTx) on IRF values
The effect of RBCTx on IRF was evaluated by comparing the IRF values obtained immediately before RBCTx (same day) and the IRF values on the subsequent day after each RBCTx administered. The period of evaluation included the day of ASCT infusion (day 0) till 1 day before doubling of the IRF. A total of 38 RBCTx were given during this period for the entire patient population. The IRF values (mean7s.d.) before and after the 38 RBCTx were 0.1270.1 and 0.1370.09, respectively (P ¼ 0.63).
Effect of Hgb level on time to IRF-D
We also examined the relationship between Hgb level and time to IRF-D by dividing patients into Hgb tertiles within each group of patients and overall (Table 3 ). Higher Hgb levels were associated with significantly earlier time to IRF-D overall and within each group of patients except for the derivation set of the 75 patients undergoing their second Mel-ASCT. This latter group had significantly higher Hgb levels than the other groups. As a result of the delayed time to IRF-D among patients with lower Hgb levels, the period between time to IRF-D and to ANCX100/ml was shorter for these patients. For the overall population, the IRF-D preceded the ANCX100/ml in each Hgb tertile (first tertile Hgbo9.7 mg/dl; second tertile Hgb 9.7-11.1 mg/dl and 
Other predictors of myeloid recovery
The time to IRF-D and IRF-N was also compared to the time to AMoCX100/ml and to PO4-20% drop among the 117 myeloma patients of the first validation set. The mean time to AMoCX100/ml was 13.3973.5 days. Only 25% of patients reached AMoCX100/ml before ANCX100/ml by a mean of 1.4870.09 days while 32% of patients reached both targets simultaneously. The remaining 43% of patients had an earlier recovery of ANCX100/ml than AMoCX100/ml. The time to AMoCX100/ml never preceded IRF-D or IRF-N. The PO4-20%-drop was reached before ANCX100/ml in 65 patients (55 %) by a mean of 2.7271.66 days. The mean time to PO4-20%-drop for these 65 patients was 9.672.18 days. The PO4-20%-drop was the first single variable predicting myeloid recovery in seven patients only (6%).
Discussion
Our results indicate that the doubling of the IRF from nadir can predict myeloid engraftment several days before ANCX100/ml among patients undergoing ASCT for a variety of underlying diseases and with different conditioning regimens.
Earlier studies have suggested that circulating immature reticulocytes can predict neutrophil recovery following chemotherapy. These studies however, utilized different methods for measuring immature reticulocytes and/or compared the IRF to ANCX500/ml and not to the more clinically relevant ANCX100/ml (Table 4) . 10, [15] [16] [17] [18] [19] [20] [21] [22] Since there are different types and manufacturers of blood count analyzers with different reference values and calibration parameters, 9, 23 end points such as doubling (IRF-D) or normalization (IRF-N) of the IRF can be used regardless of equipment and would simplify and standardize result interpretation among investigators.
Other predictors of marrow recovery, AMoCX100/ml and hypophosphatemia 6 were not as predictive of marrow recovery as IRF-D or IRF-N. We therefore recommend the use of IRF-D or IRF-N for an earlier prediction of marrow recovery and have adopted the use of the IRF in our daily clinical practice.
Red blood cell transfusion did not appear to affect the IRF values. However, the time to IRF-D was one day longer for patients with lower Hgb levels probably reflecting a poor bone marrow reserve. Even among these patients, the IRF-D still preceded ANC recovery.
Routine measurement of the IRF following chemotherapy is likely to have a significant impact on patient management. A neutropenic patient with fever and increasing IRF values is expected to reach ANCX100/ml within an average of 4 days and could be managed more conservatively, and without additional testing or intensive empirical therapies, 4 unless otherwise clinically warranted. By contrast, a febrile neutropenic patient with persistently low IRF values is more likely to have prolonged neutropenia and can therefore be targeted for intensive diagnostic, prophylactic and therapeutic measures, if clinically indicated. The IRF-N can be particularly useful in patients lacking the daily reticulocyte values needed to calculate the IRF-D.
Our findings also have implications for clinical research including the identification of high-risk patients for enrollment into clinical trials of antimicrobial agents. Concerns about including patients with impending marrow recovery into trials evaluating the efficacy of antimicrobial agents have hampered our ability to assess the true efficacy of the agent used vs the beneficial effect of resolving neutropenia. The IRF tests will likely enhance our ability to determine the role of these two factors and thus potentially reduce the sample size required for such studies. 24, 25 In conclusion, our data suggest that the IRF, a simple, reproducible, inexpensive and widely available test, can predict myeloid recovery several days before circulating ANCX100/ml in most patients undergoing autologous stem cell transplantation. The IRF could potentially be useful in the management of neutropenic cancer patients and in the investigation of antimicrobial therapies in this setting. Prospective trials assessing the contribution of the IRF to the clinical management of ASCT patients are warranted.
